SMART (Stockholm MAmmography Risk stratified Trial) is a phase 2 study conducted at the mammography unit at Södersjukhuset (Stockholm South General Hospital), Sweden. The purpose of the study is to test if individualized, risk-based breast cancer screening is superior to current practice in Sweden. In SMART we will test if an individualized, imaging-based AI screening model is a more effective way of detect women with the highest risk of developing breast cancer in the next two years. The SMART study is expected to enroll 70,000 women who will join following their regularly scheduled bi-annual mammogram. The SMART study starts to enroll participant during 2024.
The researchers in SMART now have the pleasure to announce that the US based company, Atossa Therapeutics inc, a clinical-stage biopharmaceutical company is going to support the study.
Please read Atossa Therapeutics press release about why they think SMART is an important study to support. Link to press release